<DOC>
<DOCNO>
EP-0004494
</DOCNO>
<TEXT>
<DATE>
19791003
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/445 A61P-9/00 C07D-405/00 <main>C07D-405/14</main> A61K-31/443 A61P-9/12 A61K-31/4427 A61K-31/44 C07D-405/14 
</IPC-CLASSIFICATIONS>
<TITLE>
derivatives of 1,3-dihydro-3-(1-(2-(2,3-dihydro-1,4-benzodioxin-2-yl)2-hydroxyethyl)piperidin-4-yl)2h-indol-2-on, process for their preparation, their use as medicaments and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
roussel uclaffr  <sep>roussel-uclaf<sep>roussel-uclaf102, route de noisy boíte postale no.993230 romainvillefr<sep>roussel-uclaf <sep>
</APPLICANT>
<INVENTOR>
clemence francois<sep>fournex robert<sep>humbert daniel<sep>clemence, francois<sep>fournex, robert<sep>humbert, daniel<sep>clemence, françois2, rue turgotf-75009 parisfr<sep>fournex, robert8, rue du commandant rivièref-75008 parisfr<sep>humbert, daniel15, rue gaston charlef-94120 fontenay sous boisfr<sep>clemence, francois<sep>fournex, robert  <sep>humbert, daniel<sep>clemence, françois2, rue turgotf-75009 parisfr<sep>fournex, robert8, rue du commandant rivièref-75008 parisfr<sep>humbert, daniel15, rue gaston charlef-94120 fontenay sous boisfr<sep>
</INVENTOR>
<ABSTRACT>
New derivatives of 1,3-dihydro 3- / 1- / 2- (2,3-dihydro 1,4-benzodioxin-2-yl) 2-hydroxy ethyl / piperidin-4-yl / 2h-indol 2-one,Their process for preparing, their application as drugs and pharmaceutical compositions containing them.The invention relates to new derivatives of 1,3-dihydro 3- / 1- / 2- (2,3-dihydro 1,4-benzodioxin-2-yl) 2-hydroxy ethyl / piperidin-4-yl / 2h-indol 2-one, their process for preparing, their application as drugs and pharmaceutical compositions containing them.The above derivatives correspond to the formula: wherein R₁ is hydrogen, chlorine, bromine, fluorine or alkoxy of 1 to 5 carbon, R₂ hydrogen.or an alkyl of 1 to 5 carbons, in racemic or optically active forms, as well as to the addition salts with the mineral or organic acids.The derivatives of the invention show a significant antihypertensive activity.
</ABSTRACT>
</TEXT>
</DOC>
